They first pointed out that CQ monotherapy failed to significantly lower tumor weight or enhance T cell infiltration in mice bearing orthotopic PDAC tumor while working with in combination with anti-PD-1 and anti-CTLA4; synergistic and potent anti-tumor activity as well as an increased anti-tumor immune response were registered. This evidence concerns the gene PDCD1 and neoplasm.